The WIV had the technical capability to engineer a SARS-CoV-2-like coronavirus
4 events · 3 assessments
Reassessed: still Verified
verdict confidence 0.90
Reassessed: Supported → Verified
verdict confidence 0.80 → 0.90
The Wuhan Institute of Virology (WIV) demonstrably possessed the methods, expertise, and infrastructure to construct SARS-CoV-2-like coronaviruses in the laboratory. Using reverse-genetics techniques pioneered by University of North Carolina virologist Ralph Baric, WIV researchers built multiple chimeric SARS-like coronaviruses — for example by grafting the spike gene of a newly discovered bat virus onto an existing viral backbone — and published this work in the peer-reviewed literature. A 2018 grant proposal (DEFUSE), co-authored with WIV, further shows the collaboration planned to engineer bat coronaviruses carrying features characteristic of SARS-CoV-2, including inserted furin cleavage sites, although that project was never funded. This general engineering capability is not seriously disputed, including by scientists who favor a natural origin for the pandemic. This capability should not be conflated with the separate and genuinely contested question of whether WIV possessed, or could have obtained, a virus close enough to SARS-CoV-2 to serve as a starting point. No known precursor in its collection carried SARS-CoV-2's distinctive features, and analyses of WIV's published chimeras found them very different from SARS-CoV-2. That backbone question — which bears on whether the pandemic virus itself could have been engineered — remains open and is treated separately.
Assessed Supported
verdict confidence 0.80
Evidence favors this claim in its general sense: the Wuhan Institute of Virology operated reverse-genetics systems for coronaviruses and had a documented record of constructing chimeric SARS-like coronaviruses, including work done in collaboration with US virologist Ralph Baric, who himself confirms WIV used these techniques to engineer viruses with altered functions. That the institute possessed the methods, expertise, and infrastructure to build a SARS-CoV-2-like coronavirus is therefore not seriously disputed even by many scientists who reject a laboratory origin for the pandemic. Where genuine disagreement remains is narrower and should not be conflated with this claim: whether a suitable close progenitor was available to serve as a starting template, and whether SARS-CoV-2's specific distinctive features (such as its furin cleavage site, absent in the institute's known relatives) lay within demonstrated engineering practice. Those questions — about whether such a virus could or would actually have been made, not about generic capability — are treated separately and remain contested.
Claim entered the graph